文献速递核素与放射性配体治疗神经核医学

225Ac-DOTA-TATE治疗肺神经内分泌肿瘤的临床前评价

Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-03-26

该研究在肺神经内分泌肿瘤小动物模型中评价了[225Ac]Ac-DOTA-TATE的放射合成、毒性、生物分布、辐射剂量学及疗效。[225Ac]Ac-DOTA-TATE以98%产率、99.8%纯度和37°C人血清孵育2天后97%稳定性合成;在H727和H69肺NENs模型中,单次给药后较对照组观察到显著肿瘤生长延迟和实验终点时间延长;毒性研究中除接受≥111 kBq的动物出现慢性进展性肾病外,5个月时所有动物表现健康。结论提示[225Ac]Ac-DOTA-TATE用于肺NENs具有显著临床转化潜力。

要点

  • [225Ac]Ac-DOTA-TATE放射合成产率98%、纯度99.8%、人血清37°C 2天稳定性97%。
  • 毒性研究中接受≥111 kBq的动物出现慢性进展性肾病。
  • H727和H69肺NENs模型中单次给药较对照组显著延迟肿瘤生长并延长实验终点时间。

核心结论

  • 结果提示[225Ac]Ac-DOTA-TATE用于肺神经内分泌肿瘤具有显著临床转化潜力。

研究设计与样本

  • 研究合成并表征[225Ac]Ac-DOTA-TATE的放射化学产率、纯度和稳定性。
  • 在非荷瘤BALB/c小鼠中测试毒性和生物分布。
  • 在荷人SSTR2阳性H727和H69肺NENs的SCID小鼠中,通过单次静脉注射[225Ac]Ac-DOTA-TATE确定疗效。
  • 利用生物分布数据计算辐射剂量学。

主要发现

  • [225Ac]Ac-DOTA-TATE以98%产率、99.8%纯度和37°C人血清孵育2天后97%稳定性合成。
  • 毒性研究中所有动物在注射后5个月表现健康,无毒性迹象,但接受≥111 kBq[225Ac]Ac-DOTA-TATE的动物出现慢性进展性肾病。
  • 生物分布研究显示主要消除途径为肾脏途径。
  • 辐射剂量学计算确定了药代动力学参数及来自225Ac及其子体的吸收α发射剂量。
  • 在两种肿瘤模型中,单次给予[225Ac]Ac-DOTA-TATE后较对照组观察到显著肿瘤生长延迟和实验终点时间延长。

临床怎么用

  • 临床前数据支持[225Ac]Ac-DOTA-TATE在肺NENs中的进一步临床转化研究。
  • 肾脏为主要消除途径,且≥111 kBq时观察到慢性进展性肾病,提示临床转化需关注肾脏毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide 177Lu ([177Lu]Lu-DOTA-TATE) is now standard care for neuroendocrine tumors that express the somatostatin receptor 2 (SSTR2) target. A recent clinical study demonstrated efficacy of the corresponding [225Ac]Ac-DOTA-TATE in patients that were refractory to [177Lu]Lu-DOTA-TATE. Herein, we report the radiosynthesis, toxicity, biodistribution (BD), radiation dosimetry (RD), and efficacy of [225Ac]Ac-DOTA-TATE in small animal models of lung neuroendocrine neoplasms (NENs). METHODS: [225Ac]Ac-DOTA-TATE was synthesized and characterized for radiochemical yield, purity and stability. Non-tumor-bearing BALB/c mice were tested for toxicity and BD. Efficacy was determined by single intravenous injection of [225Ac]Ac-DOTA-TATE into SCID mice-bearing human SSTR2 positive H727 and H69 lung NENs. RD was calculated using the BD data. RESULTS: [225Ac]Ac-DOTA-TATE was synthesized with 98% yield, 99.8% purity, and displayed 97% stability after 2 days incubation in human serum at 37 °C. All animals in the toxicity study appeared healthy 5 months post injection with no indications of toxicity, except that animals that received ≥111 kBq of [225Ac]Ac-DOTA-TATE had chronic progressive nephropathy. BD studies revealed that the primary route of elimination is by the renal route. RD calculations determined pharmacokinetics parameters and absorbed α-emission dosages from 225Ac and its daughters. For both tumor models, a significant tumor growth delay and time to experimental endpoint were observed following a single administration of [225Ac]Ac-DOTA-TATE relative to controls. CONCLUSIONS: These results suggest significant potential for the clinical translation of [225Ac]Ac-DOTA-TATE for lung NENs.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tafreshi NK, Pandya DN, Tichacek CJ, et al. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021. PMID: 33772332. doi:10.1007/s00259-021-05315-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。